Pembrolizumab vs Rasagiline Mesylate
Pembrolizumab vs Rasagiline Mesylate: Overview
This comparison examines the pharmacological differences between Pembrolizumab and Rasagiline Mesylate.
Mechanism of Action
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Pharmacokinetics
Half-life: Pembrolizumab β 26 days.
Chemical Properties
Type: Pembrolizumab β Antibody; Rasagiline Mesylate β Small molecule.